Abstract

MUCORMYCOSIS TREATMENT AND DIAGNOSIS: A REVIEW (RELATED TO COVID-19)

Akanksha Shinde*, Mayuri Urhe, Vrishali Diwate, Shubhodika Dond Pranav Shelke and Vishal Rathod

Abstract

In COVID-19 situation recently observed the a fungal infection called as mucormycosis. This mucormycosis that is black fungus, this black fungus commonly observed in those patients who are recovering from COVID-19 in an India. Mucormycosis is fungal disease. Mucormycosis is also known as zygomycosis. Refer to many fungal disease in order mucorales. Causative organisms of mucormycosis is a Rhizopus species and other species include Mucor, canninghamella, Apophysomyces, lichtheimia, saksenaea, Rhizomucos etc. An epidemiology of mucormycosis has been seen in recent years with rise in incidence. Due to new causative agents and easy target population the spread in Asian countries is very high. Patients with diabetes mellitus are mostly the victims of mucormycosis. The new risk of mucormycosis is post - tuberculosis and chronic renal failure. In immunocompetent hosts, cutaneous mucormycosis is commonly seen. The intriguing clinical entity, isolated renal mucormycosis In immunocompetent patients is only seen in China and India. The causative agents of mucormycosis depends on the geographical location. Though Rhizopus arrhizals is common agent over world. Apophysomyces variabilis is predominant In Asian countries and Lichtheimia species is observed in Europe. Thamnostylum luchnowense observed in Asia. Mostly Amphotericin B is used in mucormycosis dose of 1-1.5 mg/kg and new antifungal such as Poraconazole.

Keywords: Apophysomyces, lichtheimia, saksenaea, Rhizomucos etc.